A global partnership, coordinated by the Karolinska Institutet and in which IDIBAPS researchers participate, has received 15 million euros from the European Commission framework program Horizon2020 to find new and improved treatments for Multiple Sclerosis (MS). This project, named MultipleMS, involves universities and companies from 12 European countries and the USA, which will join efforts to adapt the development and application of therapies to each MS patient.
Researchers at IDIBAPS and the Imperial College London publish a study in which they have discovered that RNA sequences that do not encode for proteins play a key role in the expression of certain genes in the beta cells of the pancreas. These genes are known to be involved in the development of different forms of diabetes. Dr. Jorge Ferrer, head of the team Genomic Programming of Beta Cells and Diabetes at IDIBAPS and at the Imperial College London and researcher at the Networked Biomedical Research Center for Diabetes and Associetaed Metabolic Diseases (CIBERDEM), coordinates this study published in the journal Cell Metabolism. Read the rest of this entry »
Hospital Clinic-IDIBAPS coordinates a European project to obtain a functional cure for HIV with immunotherapy
The IDIBAPS and the Hospital Clínic of Barcelona lead a European project aimed at changing the current paradigm of HIV treatment by obtaining a functional cure. The main goal is to control HIV replication over long periods of time or throughout life without antiretroviral treatment. Dr. Felipe Garcia, senior consultant of the Infectious Diseases Department at Hospital Clínic and researcher of the IDIBAPS team on Infectious Diseases and AIDS, coordinates this study called HIVACAR. This initiative is part of the European research and innovation framework program Horizon 2020, has a total budget of 6.7 million euro and 14 institutions will participate, among clinical and research centers and European companies. In Spain, the other participating institutions are the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology (CNB-CSIC) and the Faculty of Economics and Business Sciences of the Complutense University of Madrid (UCM). Read the rest of this entry »
Drs. Francesc Artigas and Analía Bortolozzi, researchers of the team of Neuropharmacology and Experimental Neuropathology in the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the IIBB-CSIC, have just published a “Hot Topic” article in the first issue of 2017 in the journal Neuropsychopharmacology, one of the most prestigious in the field of Psychiatry and Neuropharmacology. This section of the journal, published at the beginning of each year, collects significant advances recently produced in the field.
The article briefly reviews the advances made by the group in the development of new experimental strategies for a more rapid and effective treatment of depression through the use of interfering RNA molecules conjugated to serotonin reuptake inhibitors. These advances were published in the journals Molecular Psychiatry and Traslational Psychiatry and show that these conjugates produce an antidepressant effect faster than the conventional drugs in experimental models, which means a remarkable advance with a possible therapeutic application.
Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder
Artigas F, Bortolozzi A.
Neuropsychopharmacology. 2017 Jan;42(1):371. doi: 10.1038/npp.2016.182.
Scientists at Salk Institute have made breakthroughs in the integration of human cells into embryos of a different species
Scientists at Salk Institute for Biological Studies in California have made breakthroughs on multiple fronts in the race to integrate pluripotent stem cells from one species into the early-stage development of another. This will allow to study the embryonic development of an organism, diseases, test new therapeutic drugs and the possibly grow transplantable. Dr. Juan Carlos Izpisúa, professor in Salk’s Gene Expression Laboratory, leads this study published in today’s issue of the journal Cell. Dr. Josep M. Campistol, CEO and nephrologist in Hospital Clínic and researcher in IDIBAPS, and scientists from the Catholic University of Murcia (UCAM), the Pedro Guillén Foundation, the CEMTRO Clinic in Madrid and the University of Murcia, have also participated.
Dr. Josep Dalmau, ICREA Professor of IDIBAPS, where he leads the Group Pathogenesis of autoimmune neuronal disorders, and consultant of the Neurology Department of Hospital Clínic, has been named Chair of the Autoimmune Neurology Section in the American Academy of Neurology (AAN). It is a newly created section that wants to differentiate itself from the classic concept of neuroimmunology, more linked to other types of diseases such as Multiple Sclerosis. The founders of the section are Drs. Sean Pittock, of the Mayo Clinic, and Jeffrey Gelfand, of the University of California San Francisco (UCSF). Read the rest of this entry »